Related Experiment Video

Updated: Dec 1, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.6K

[Gastrointestinal Bleeding in Patients with Coronary Heart Disease: Preventive Options]

N S Lapina1, A A Alekseeva1, A D Vershinina1

  • 1Privolzhsky Research Medical University of the Ministry of Health of Russia, Nizhny Novgorod.

Kardiologiia
|November 6, 2020
PubMed

Insights

Antithrombotic drugs (ATD) reduce cardiovascular risks in ischemic heart disease (IHD) but increase gastrointestinal bleeding (GIB) risk. Risk assessment and individualized management are crucial for patient safety.

Area of Science:

  • Cardiology
  • Gastroenterology
  • Pharmacology

Background:

  • Antithrombotic drugs (ATD) are extensively used in ischemic heart disease (IHD) to prevent cardiovascular events.
  • ATD use is associated with a significant risk of gastrointestinal bleeding (GIB), affecting 0.5-1.0% of patients.

Purpose of the Study:

  • To outline strategies for preventing and managing gastrointestinal bleeding (GIB) in patients with ischemic heart disease (IHD) undergoing antithrombotic drug (ATD) therapy.
  • To emphasize the importance of risk assessment and individualized patient management.

Main Methods:

  • Adherence to ATD treatment indications.
  • Identification and mitigation of GIB risk factors.
  • Utilizing risk assessment scales like PRECISE-DAPT, DAPT, and HAS-BLED.
  • Individualized therapeutic strategies for non-modifiable risk factors.
  • Continuous patient monitoring for gastrointestinal complications.

Main Results:

  • Strict adherence to ATD indications and risk factor management can decrease GIB incidence.
  • Risk stratification using validated scales aids in predicting and preventing GIB.
  • Individualized treatment plans are essential when risk factors are non-modifiable.

Conclusions:

  • Effective prevention and management of GIB in IHD patients on ATD require a multifaceted approach.
  • Risk assessment tools and tailored management strategies are vital for patient safety.
  • Ongoing monitoring is necessary for timely detection and treatment of GI complications.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.0K
Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

496

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
261
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
254
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
143
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
494
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
867
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.0K